Advent Therapeutics

Executive Summary

Advent Therapeutics is a late-stage biopharmaceutical company dedicated to developing life-saving therapies for extremely preterm infants, with a primary focus on bronchopulmonary dysplasia (BPD). The company's proprietary formulations of retinol palmitate (vitamin A) aim to address the severe metabolic and reparative needs of fragile neonates. BPD is a chronic lung disease affecting up to 50% of infants born before 28 weeks gestation, with no approved therapies. Advent's approach builds on established evidence that vitamin A supplementation reduces BPD risk, but existing formulations pose toxicity and delivery challenges. The company's optimized retinol palmitate formulations are designed to provide safe, targeted delivery, potentially setting a new standard of care. As a late-stage entity, Advent is poised to advance its lead candidate through clinical development, leveraging strong preclinical and early clinical data.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 top-line data readout for lead retinol palmitate formulation55% success
• Q3 2026FDA meeting to discuss pivotal trial design for BPD indication70% success